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The mechanisms by which tumor-responsive CD8+ T cells are regulated are important 
for understanding the tumor immunity and for developing new therapeutic strategies. In 
current study, we identified the expression of 1810011o10 Rik, which is the homolog of 
human thyroid cancer 1, in intratumoral activated CD8+ T cells in a murine hepatocellular 
carcinoma (HCC) implantation model. To investigate the role of 1810011o10 Rik in the 
regulation of antitumor activity of CD8+ T cells, normal CD8+ T cells were transduced with 
1810011o10 Rik-expressing lentiviruses. Although 1810011o10 Rik overexpression did 
not influence agonistic antibody-induced CD8+ T cell activation in vitro, it inhibited the 
cytotoxic efficacy of CD8+ T cells on HCC cells in vivo. 1810011o10 Rik overexpression 
impeded CD8+ T cell-mediated HCC cell apoptosis and favored tumor cell growth in vivo. 
Further investigation revealed that 1810011o10 Rik blocked the nuclear translocation of 
Notch2 intracellular domain, which is crucial for CD8+ T cell activity. Furthermore, a brief 
in vitro experiment suggested that both antigen-presenting cells and TGF-β might be 
necessary for the upregulation of Rik expression in activated CD8+ T cells. In general, 
our study disclosed a novel mechanism underlying the negative regulation of antitumor 
CD8+ T cells during HCC progression.
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inTrODUcTiOn
Adaptive immune response is critical for surveillance, confinement, and elimination of malignant 
liver cells that give rise to hepatocellular carcinoma (HCC). Among the adaptive immune cells, both 
CD4+ T helper cells and CD8+ cytotoxic T cells are mostly considered to be significant players in 
inhibiting, impeding, and killing tumor cells (1). Furthermore, it is generally accepted that CD8+ 
T cells are the fundamental adaptive immune cells that monitor and kill tumor cells (2). However, 
the mechanisms by which the functions of tumor-responsive CD8+ T cells are regulated in tumor 
sites are still not thoroughly understood. Accumulative evidence suggests suppression or even loss 
of antitumor ability of CD8+ T cells in individuals with HCC (3). The suppressive factors in the 
tumor microenvironment might include cellular components, such as CD4+ regulatory T  cells 
(4, 5), CD8+ regulatory T cells (6), Th17 cells (7), Kupffer cells (8), myeloid-derived suppressor cells 
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(9, 10), and humoral components, such as IL-10 (11), TGF-β (12), 
and amphiregulin (13). It is of great importance to elucidate and 
manipulate the regulatory mechanisms of CD8+ T cell activity, so 
as to develop novel therapeutic strategies to treat HCC.
Thyroid cancer 1 (TC1), as known as C8orf4, is a 106-resi-
due naturally disordered protein, which was originally cloned 
from subtractive hybridization between a papillary thyroid 
cancer and its surrounding normal thyroid tissue. Considered 
as a multi-functional protein involved in cell cycle control and 
transcriptional and translational regulation, TC1 has been shown 
to be correlated with growth and differentiation of various types 
of malignant cells, including thyroid cancer, ovarian carcinomas, 
gastric cancers, squamous cell carcinomas, and HCC (14–19). 
In particular, TC1 negatively regulates the self-renewal of liver 
cancer stem cells (19). Moreover, recent findings have suggested 
the regulatory role of TC1 in normal cell types such as follicular 
dendritic cells and hematopoietic stem/progenitor cells (20, 21). 
However, the role of TC1 in T cell development or function has 
never been reported.
In current study using a mouse HCC implantation model, we 
identified the expression of 1810011o10 Rik (hereinafter Rik), 
which is the homolog of human TC1, in intratumoral activated 
CD8+ T cells. To investigate the role of Rik in the regulation of 
antitumor activity of CD8+ T  cells, normal CD8+ T  cells were 
transduced with Rik-expressing lentiviruses. Although Rik over-
expression did not influence agonistic antibody-induced CD8+ 
T cell activation in vitro, it inhibited the cytotoxic efficacy of CD8+ 
T cells on tumor cells in vivo. Rik-overexpressing CD8+ T cells 
were inefficient in inducing tumor cell apoptosis and suppressing 
tumor growth in vivo. In-depth investigation revealed that Rik 
blocked the nuclear translocation of Notch2 intracellular domain 
(NICD2) which is crucial for CD8+ T cell activity. Furthermore, a 
brief experiment indicated that both antigen-presenting cells and 
TGF-β might be necessary for the upregulation of Rik expression 
in activated CD8+ T cells. In general, our study disclosed a novel 
mechanism underlying the negative regulation of antitumor 
CD8+ T cells in HCC.
MaTerials anD MeThODs
Tumor cell culture and Tumor 
implantation Model
Mouse HCC cell lines Hepa-1c1c7, Hepa1-6, and c12 were pur-
chased from American Type Culture Collection and were main-
tained in Dulbecco’s modified Eagle’s medium supplemented 
with 10% fetal bovine serum in a 37°C humidified incubator.
All animal experiments were conducted in compliance with 
institutional guidelines and Wuhan University Guidelines for 
the Use of Animals. All animal procedures were approved by 
the Wuhan University School of Medicine Animal Care and Use 
Committee. C57BL/6 and BALB/c mice were purchased from 
Vital River Laboratories (Beijing, China). Rag1−/− mice (C57BL/6 
background) were purchased from Shanghai Model Organisms 
Center, Inc. Six- to eight-week-old male mice were used in all 
experiments. All mice were housed under controlled temperature 
and light conditions following the Institutional Animal Care 
guidelines. For tumor implantation, 3 × 106 HCC cells in 60 μl 
of phosphate-buffered saline (PBS) were subcutaneous injected 
into the dorsal skin of immunocompetent C57BL/6 mice or 
Rag1−/− mice.
isolation of T cells from Tumor implants
Briefly, mice were euthanized by inhalation of carbon dioxide for 
an average of 5 min, followed by perfusion with 20 ml of ice-cold 
PBS through the right ventricle of the heart. The subcutaneous 
tumor implant was taken and minced into small pieces with sur-
gical scissors before incubation on an orbital shaker for 30 min at 
37°C in 5 ml of RPMI medium containing 1 mg/ml Collagenase 
IV (Thermo Fisher Scientific, 17104019), 4 mM CaCl2, and 10% 
fetal bovine serum (Hyclone, SH30088.02). After that, the tumor 
tissue was pressed through a 70-μm nylon mesh and centrifuged at 
250 g for 5 min. The tissue pellet was resuspended in 5 ml of RPMI 
medium and overlaid onto 70% Percoll solution (GE Healthcare, 
17-0891-09). After 15 min of centrifugation at 500 g, cells in the 
interlayer were collected, washed twice with PBS, and subject to 
further experiments. In some experiments, cells isolated from six 
to eight tumor implants were pooled for investigation.
Flow cytometry
To analyze the splenic and intratumoral T cells, the following anti-
bodies were used: PE anti-CD3 (561799), PE anti-CD4 (561829), 
APC-Cy7 anti-CD8a (561967), FITC anti-CD44 (553133), 
Percp-Cy5 anti CD62L (560513), PE anti-TNF-α (561063), APC 
anti-CD45 (561018), APC anti-CD31 (561814), PE anti-Notch1 
(562754), PE anti-Notch2 (562755), FITC Annexin V (556419), 
and propidium iodide (556463) were from BD Bioscience. APC 
anti-TCRβ (17-5961), PE-Cy7 anti-granzyme B (25-8898), PE 
anti-perforin (12-9392), and FITC anti-Ki67 (11-5698) were 
ordered from eBioscience. All antibodies were 1:100 diluted 
before use unless specified. For cell surface staining, cells were 
incubated in antibody-containing PBS for 15 min on ice before 
test on a Beckman Coulter Cytomics FC500 Flow Cytometry 
Analyzer. Dead cells were excluded with 1  μg/ml propidium 
iodide. For intracellular cytokine and Ki67 staining, cells were 
fixed with 4% paraformaldehyde for 15 min at room temperature, 
permeabilized with 90% ice-cold methanol for 30 min on ice and 
were then stained at room temperature for 1 h with corresponding 
cytokine antibodies. The data were analyzed using a Cell Quest 
Pro software. Cell sorting was done by a BD FACSAria cell sorter.
rna extraction, cDna synthesis, and 
Quantitative Polymerase chain reaction
Cells or tissues were lysed in Trizol reagent (Thermo Fisher 
Scientific, 15596026), and RNAs were extracted following the 
manufacturer’s protocol. Two micrograms of RNA from each sam-
ple were used for cDNA synthesis using the SuperScript® III First-
Strand Synthesis System (Thermo Fisher Scientific, 18080051) 
following the manufacturer’s protocol. qRT-PCR was conducted 
using Fast SYBR® Green Master Mix (Thermo Fisher Scientific, 
4385610) on a StepOnePlus™ Real-time PCR System (Thermo 
Fisher Scientific, 4376374). Primer pairs used for amplification are 
as follows: β-actin (5′-AGAGGGAAATCGTGCGTGAC-3′ and 
5′-CAATAGTGATGACCTGGCCGT-3′); TNF-α (5′-GCCTCT 
TCTCATTCCTGCTTG-3′ and 5′-CTGATGAGAGGGAGGC 
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CATT-3′); perforin (5′-CTGGCAGGGACGATGACCT-3′ and 
5′-GGGAACCAGACTTGGGAGC-3′); granzyme B (5′-ATCA 
AGGATCAGCAGCCTGA-3′ and 5′-TGATGTCATTGGAGA 
ATGTCT-3′); HES1 (5′-ATAGCTCCCGGCATTCCAAG-3′ and 
5′-GTATTTCCCCAACACGCTCG-3′); HES6 (5′-AAGCCCC 
TGGTGGAGAAGAA-3′ and 5′-TTGGCCTGCACCTCG 
GTA-3′); and HEY1 (5′-GTGGGAAAGGGATGGTTGAG-3′ 
and 5′-GAGGAGTTAACTGCAGTGGC-3′). Relative abun-
dance of RNA was analyzed using 2−ΔΔCt method.
immunoblot
Extraction of whole cell proteins was conducted using RIPA 
buffer (20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 
1 mM EGTA, 1% NP-40, 1% sodium deoxycholate) containing 
protease inhibitors (Sigma-Aldrich, SRE0055-1BO). Extraction 
of cytosolic and nuclear proteins was conducted using the 
ReadyPrep protein extraction kit (Bio-Rad, 1632089) according 
to the manufacturer’s manual. Proteins were quantified using 
Pierce 660 nm Protein Assay Reagent (Thermo Fisher Scientific, 
22660). Immunoblot was performed using the protocol as 
previously described (22). The lysates were loaded onto 4–20% 
Mini-PROTEAN® TGX™ Precast Gels (Bio-Rad, 4561091). 
The following antibodies were used: anti-β-actin (Santa Cruz 
Biotechnology, sc-130300), anti-TC1 (Santa Cruz Biotechnology, 
sc-98165), anti-caspase-3 (Cell Signaling Technology, 9662), anti-
cleaved caspase-3 (Cell Signaling Technology, 9664), anti-Notch1 
(Cell Signaling Technology, 4380), anti-Notch2 (Santa Cruz 
Technology, sc-5545), anti-NICD1 (Cell Signaling Technology, 
4147), and anti-NICD2 (Sigma-Aldrich, SAB4502022). The dilu-
tions of the antibodies were based on the manufacturers’ instruc-
tions. The membranes were developed using SuperSignal West 
Femto Chemiluminescent Substrate (Thermo Fisher Scientific, 
34095). The optical density was analyzed using a BioSpectrum 
500 imaging system (Ultra-Violet Products Ltd.).
immunoprecipitation
CD8+ T  cells were lysed in 50mM Tris–HCl (pH7.4), 150mM 
NaCl, 0.5% NP-40, and protease inhibitors (Sigma-Aldrich, 
SRE0055-1BO) for 30 min on ice followed by centrifugation at 
3,000 g for 5 min at 4°C. The supernatant containing a total of 
500  μg proteins was collected for immunoprecipitation. One 
milligram of Dynabeads™ Protein A (Thermo Fisher Scientific, 
10001D) was coupled to 5 mg anti-TC1 (Santa Cruz Biotechnology, 
sc-98165) antibody following the manufacturer’s manual. The 
supernatant was mixed with 1  mg anti-TC1 antibody-coupled 
Dynabeads, incubated overnight at 4°C on a rotator, and eluted 
in a low pH buffer. The elution was mixed with 2× Laemmli 
buffer before being boiled for 5 min and was then loaded onto an 
8% SDS-PAGE gel for Immunoblot with anti-NICD2 antibody 
(Sigma-Aldrich, SAB4502022).
immunofluorescent staining
Cell suspensions were air dried on poly-l-lysine-coated glass 
slides before fixation in 4% paraformaldehyde for 15 min at room 
temperature. The cells were then washed three times in PBS and 
blocked with PBS containing 10% goat serum and 0.1% Triton 
X-100 for 1  h. Anti-Notch2 (Santa Cruz Technology, sc-5545) 
antibody was diluted in 0.1% Triton X-100-PBS and was used 
to incubate cells overnight at 4°C. Cells were then washed three 
times in PBS followed by incubation with FITC-conjugated goat 
anti-rabbit IgG (Abcam, ab6717) for 1  h at room temperature. 
Cells were then washed two times in PBS and mounted with 
ProLong® Gold Antifade Mountant (Thermo Fisher Scientific, 
P36930). Cells were observed on an Olympus BX51 fluorescence 
microscope.
Terminal Deoxynucleotidyl Transferase 
dUTP nick end labeling (TUnel)
The mice were sacrificed and perfused with 30 ml of 10% formalin. 
Tumor implants were taken for further fixation in 10% formalin 
overnight, followed by routine processing of dehydration and 
paraffin embedding. The 5-μm sections were prepared on a HMT-
2258 Manual Rotary Microtome. TUNEL was performed using 
the DeadEnd™ Fluorometric TUNEL System (Promega, G3250) 
following the manufacturer’s recommendations. The sections 
were observed on an Olympus BX51 fluorescence microscope.
enrichment of splenic cD8+ T cells and 
Depletion of T cells from splenocytes
Splenic CD8+ T cells were enriched from mice at day 10 to day 12 
after HCC inoculation using the MojoSort™ Mouse CD8 T Cell 
Isolation Kit (Biolegend, 480008) following the manufacturer’s 
manual. Depletion of T cells from splenocytes was done through 
negatively selection using CD3 staining and flow cytometry 
sorting.
In Vitro T cell culture and Treatment
CD8+ T cells were cultured at the cell density of 1 × 106/ml in 
supplemented RPMI 1640 (containing 10% fetal bovine serum, 
2 mM l-glutamine, 100 U/ml penicillin, and 100 μg/ml strepto-
mycin) before further experiments. For coculture of T cells with 
tumor cells, 2.5 ×  104 Hepa-1c1c7 cells were cultured in each 
well of a 96-well round-bottom culture plate for 6 h, followed by 
addition of 2.5 × 104 CD8+ T cells and incubated for another 24 h. 
Floating cells were collected, and adherent cells were then lifted 
and flushed by 0.25% Trypsin-EDTA (Thermo Fisher Scientific, 
25200056) for 3 min at 37°C. Floating and flushed adherent cells 
were pooled for CD45 and Annexin V staining.
For lentiviral transduction, a 24-well culture plate was 
coated with 5  μg/ml anti-CD3 monoclonal antibody (eBiosci-
ence, 16-0032-82). A total of 1 × 106 sorted CD8+ T cells were 
seeded into each well in the presence of 2  μg/ml anti-CD28 
antibody (eBioscience, 16-0281-81) and 100 U/ml recombinant 
mouse IL-2 (eBioscience, 14-8021-64). At day 4 of stimulation, 
5 μg/ml polybrene and 1810011O10 Rik lentiviral vector (MOI: 
20, abm Inc., LV442947) were added into the culture. After over-
night incubation, cells were washed with medium and stimulated 
the same way for additional 3 days. In some experiments, CD8+ 
T cells were labeled with 5 μM 5-(and 6)-carboxyfluorescein diac-
etate succinimidyl ester (CFSE, eBioscience, 65-0850-84) before 
stimulation. For intracellular staining, cells were treated with 
20 ng/ml phorbol ester (Sigma-Aldrich, P1585-1MG) and 1 μM 
ionomycin (Sigma-Aldrich, I0634-1MG) with 5 μg/ml brefeldin 
FigUre 1 | intratumoral cD8+cD44+cD62l− T cells express rik. (a) Flow cytometry gating strategy of splenic and intratumoral CD4+ and CD8+ T cells. Total 
T cells were gated based on TCR staining and were subsequently discriminated by CD4 and CD8 staining. Numbers in the plots are proportions of gated cell 
populations. (B) Representative dot plots showing expression of CD44 and CD62L on splenic and intratumoral CD4+ and CD8+ T cells. Numbers in the plots are 
proportions of gated cell populations. (c) Rik mRNA level in splenic and intratumoral CD4+ and CD8+ T cells. N = 5 per group. (D) Rik protein expression in splenic 
and intratumoral CD4+ and CD8+ T cells. This is a representative image of two independent experiments. ***p < 0.001 compared with splenic CD4+CD44−CD62L+ 
cells.
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A (Sigma-Aldrich, B5936-200UL) and 5 μg/ml monensin (Sigma-
Aldrich, M5273-500MG) for the last 4 h of stimulation.
For Notch signaling detection, a 24-well culture plate was 
coated with 10 μg/ml recombinant mouse delta-like 1 (DLL1) Fc 
chimera protein (R&D Systems, 5026-DL) overnight at 4°C. A 
total of 2 × 106 sorted CD8+ T cells were seeded into each well 
and incubated for 1 h before immunoblot and 4 h before RNA 
extraction, respectively.
For coculture of CD8+ T  cells with T  cell-free splenocytes, 
T cell-free splenocytes were acquired from BALB/c mice and were 
treated with 25  μg/ml Mitomycin C (Sigma-Aldrich, M4287-
2MG) at 37°C for 30 min. Then, splenocytes were washed three 
times with PBS and 2 × 106 splenocytes were plated into each well 
of a 24-well culture plate. A total of 2 × 106 CD8+ T cells were sorted 
from C57BL/6 mice and were plated into each well. In some wells, 
recombinant mouse TGF-β (R&D systems, 7666-MB-005) was 
added into culture at 10 ng/ml. The plate was centrifuged at 250 g 
for 5 min. Cells were incubated for 6 days. Then, the whole culture 
was stained with APC anti-CD3 antibody, and CD3+ T cells were 
sorted by flow cytometry for Immunoblot.
adoptive Transfer
To track the recruitment of Rik-overexpressing CD8+ T  cells, 
these cells were labeled with CellTrace Far Red (Thermo Fisher 
Scientific, C34572) according to the manufacturer’s manual. A 
total of 5 ×  106 labeled Rik-overexpressing CD8+ T  cells and 
FigUre 2 | cytotoxic activity of intratumoral cD8+cD44+cD62l− and cD8+cD44−cD62l+ T cells. (a,B) Expression of TNF-α, granzyme B, and perforin in 
intratumoral CD8+ T cell subpopulations was analyzed by intracellular staining. Representative dot plots were shown in panel (a), and statistical analysis was 
demonstrated in panel (B). N = 3 per group. (c) Hepa-1c1c7 cell apoptosis after 24-h coculture with intratumoral CD8+ T cell subpopulations. The whole cells were 
stained with APC anti-CD45 antibody and FITC Annexin V. Only CD45-negative tumor cells were shown in the dot plots. This is a representative image of three 
independent experiments. Numbers in the plots are proportions of gated cell populations. Alone: tumor cells cultured alone. CD44−CD62L+: tumor cells cocultured 
with CD8+CD44−CD62L+ T cells. CD44+CD62L−: tumor cells cocultured with CD8+CD44+CD62L− T cells. A-V, Annexin V (***p < 0.001).
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5 × 106 unlabeled control CD8+ T cells were mixed in 100 μl of 
PBS before infusion into tumor-bearing Rag1−/− mice through 
retro-orbital injection. Three days after transfer, intratumoral 
T cells from individual mouse were pooled and analyzed.
To analyze the role of Rik in CD8+ T cell-mediated antitumor 
function, at day 21 after tumor inoculation in Rag1−/− mice, 1 × 107 
CD8+ T cells in 100 μl of PBS were transferred into each mouse 
via retro-orbital injection. The injection was conducted twice a 
week for two consecutive weeks. One week after the last injec-
tion, the mice were sacrificed for evaluation of tumor growth. The 
tumor volume was measured according to the standard formula 
1/2 × L × W2.
FigUre 3 | Overexpression of rik does not influence cD8+ T cell activation in vitro. (a) Expression of Rik after lentiviral transduction. N: naïve CD8+ T cells. 
A: agonistic antibody-stimulated CD8+ T cells. Ctrl: no transduction. L-S: transduction with lentiviruses containing scramble sequence. L-R: transduction with 
lentiviruses containing Rik sequence. This is a representative image of two independent experiments. (B) CFSE dilution in lentivirus-transduced CD8+ T cells. Left 
panel: representative histograms. Right panel: statistics of mean fluorescent intensity. (c,D) Intracellular staining of TNF-α (c), granzyme B and perforin (D) in 
lentivirus-transduced CD8+ T cells. Numbers in the plots are proportions of gated cell populations. N: naïve CD8+ T cells. A: agonistic antibody-stimulated CD8+ 
T cells. L-S: transduction with lentiviruses containing scramble sequence. L-R: transduction with lentiviruses containing Rik sequence. (e) Statistical analysis of the 
proportions of CD8+ T cells expressing TNF-α, granzyme B, and perforin. N = 5 per group. (F) CD8+ T cell apoptosis after stimulation and lentiviral transduction. A-V, 
Annexin V; PI, propidium iodide. This is a representative image of two independent experiments.
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FigUre 4 | continued
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FigUre 4 | continued 
rik inhibits cytotoxic activity of activated cD8+ T cells in vivo. (a) CD8+ T cell mixture before adoptive transfer. CD8+ T cells transduced with Rik-expressing 
lentiviruses were labeled with CellTrace Far Red and were then mixed with equivalent number of unlabeled CD8+ T cells transduced with lentiviruses containing 
scramble sequence. Proportion of each CD8+ T cell subpopulation was shown in the dot plot. (B,c) Proportions of labeled and unlabeled CD8+ T cells in tumor 
implants. Intratumoral T cells were distinguished by TCR staining and CellTrace Far Red signal. Representative dot plots were shown in panel (B), and statistical 
analysis was shown in panel (c). L-S: CD8+ T cells transduced with lentiviruses containing scramble sequence. L-R: CD8+ T cells transduced with lentiviruses 
containing Rik sequence. Numbers in the plots are proportions of gated cell populations. N = 3 per group. (D,e) Expression of TNF-α (D), granzyme B and perforin 
(e) in transferred CD8+ T cells isolated from tumor implants. Note that these cells were not stimulated in vitro with phorbol ester. Left panels: representative dot 
plots. Right panels: statistics. Numbers in the plots are proportions of gated cell populations. N = 6 per group. (F) Hepa-1c1c7 cell apoptosis after 24-h coculture 
with transferred CD8+ T cells isolated from tumor implants. Alone: tumor cells cultured alone. L-S: tumor cells cocultured with control CD8+ T cells. L-R: tumor cells 
cocultured with Rik-overexpressing CD8+ T cells. Upper panel: representative dot plots. Lower panel: statistics of PI+ or Annexin V+ tumor cells. N = 4 per group 
(**p < 0.01; ***p < 0.001).
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statistical analysis
Quantitative data were expressed as mean  ±  SEM from the 
indicated number of experiments. Student’s t-test or one-way 
ANOVA was used for comparison of mean between the groups. 
p Values <0.05 were considered significant.
resUlTs
rik is Predominantly expressed in 
intratumoral activated cD8+ T cells
To determine the expression of Rik in intratumoral T cells, mice 
were inoculated with Hepa-1c1c7 cells and intratumoral T cells 
were isolated for analysis. In immunocompetent C57BL/6 mice, 
subcutaneously injected Hepa-1c1c7 cells formed tumor implants 
1 week after inoculation, but these tumor implants disappeared 
within 2  weeks after inoculation, probably being eradicated by 
antitumor immune reactions. Therefore, intratumoral T  cells 
were analyzed between day 8 and day 10 post-inoculation when 
tumor implants still existed. Analysis of the activation markers 
demonstrated that over 40% of either CD4+ or CD8+ intratumoral 
T cells were phenotypically activated T cells (CD44+CD62L−), in 
comparison with the low frequency of splenic activated T cells 
(Figures  1A,B). qRT-PCR assay indicated that intratumoral 
CD8+CD44+CD62L− T  cells expressed substantially higher 
Rik mRNA level than all other splenic and intratumoral T cell 
subpopulations (Figure 1C). Consistently, Rik protein was pre-
dominantly detected in intratumoral CD8+CD44+CD62L− T cells 
(Figure 1D). This phenomenon was also seen in tumor implants 
formed by other two HCC cell lines (Figure S1 in Supplementary 
Material). Since Hepa-1c1c7 cells formed relatively larger tumor 
implants than the other two cell lines (data not shown), we chose 
Hepa-1c1c7 cells for the following experiments.
cD8+cD44+cD62l− T cells are hcc-
reactive T cells
To ascertain the anti-HCC activity of intratumoral 
CD8+CD44+CD62L− T  cells, expression of cytotoxic mediators 
in intratumoral CD8+CD44−CD62L+ and CD8+CD44+CD62L− 
T  cells were assessed through intracellular staining. Very 
few CD8+CD44−CD62L+ T  cells expressed TNF-α and per-
forin, whereas approximately 25% of CD8+CD44−CD62L+ 
T  cells expressed granzyme B. However, the frequencies of 
CD8+CD44+CD62L− T  cells which expressed these cytotoxic 
mediators were remarkably higher (26% expressing TNF-α, 
50% expressing granzyme B, and 22% expressing perforin), 
suggesting that CD8+CD44+CD62L− T  cells were cytotoxic 
T cells (Figures 2A,B). To further test their reactivity to HCC, 
these T  cell subpopulations were cocultured with Hepa-1c1c7 
cells before Hepa-1c1c7 apoptosis was evaluated. As shown 
in Figure S2 in Supplementary Material and Figure  2C, 
CD8+CD44−CD62L+ T  cells moderately induced Hepa-1c1c7 
cell apoptosis in comparison to Hepa-1c1c7 cells cultured alone, 
while CD8+CD44+CD62L− T  cells robustly caused Hepa-1c1c7 
cell apoptosis. These data indicated that CD8+CD44+CD62L− 
T cells were potent HCC killers.
rik Does not alter agonistic antibody-
induced cD8+ T cell activation In Vitro
To evaluate the role of Rik in CD8+ T  cell activation, splenic 
CD8+ T  cells isolated from tumor-bearing mice were activated 
with immobilized anti-CD3 and soluble anti-CD28 antibodies 
and were subsequently transduced with lentiviruses expressing 
Rik. Overexpression of Rik was substantiated by Immunoblot 
(Figure 3A; Figure S3 in Supplementary Material). Interestingly, 
agonistic antibody-induced CD8+ T  cell activation itself could 
not increase Rik expression (Figure 3A), suggesting that CD3/
CD28 signaling were not sufficient to induce Rik expression. 
Furthermore, Rik overexpression did not impact T  cell prolif-
eration (Figure 3B). In naive T cells, transduction of lentiviruses 
with or without Rik sequence did not upregulate production of 
TNF-α, granzyme B, and perforin (Figures  3C–E), suggesting 
that lentiviral transduction had no effect on expression of cyto-
toxic mediators in resting CD8+ T cells. Notably, in comparison 
with control lentiviruses (L-S), transduction of Rik-expressing 
lentiviruses (L-R) did not change the expression of TNF-α, gran-
zyme B, and perforin in activated CD8+ T cells (Figures 3C–E). 
Moreover, Rik overexpression did not remarkably alter CD8+ 
T cell apoptosis (Figure 3F). Taken together, our data indicated 
that Rik expression did not influence agonistic antibody-induced 
CD8+ T cell activation.
rik inhibits antitumor activity of cD8+  
T cells In Vivo
To assess the effects of Rik on CD8+ T  cell function in  vivo, 
Rik-overexpressing CD8+ T  cells were labeled with CellTrace 
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FigUre 5 | continued
FigUre 5 | continued 
rik expression in cD8+ T cells favors tumor survival. (a) Tumor size. C: control mice receiving phosphate-buffered saline. L-S: mice receiving CD8+ T cells 
transduced with scramble lentiviruses. L-R: mice receiving CD8+ T cells transduced with Rik-expressing lentiviruses. Each circle represents an individual mouse.  
(B) mRNA levels of TNF-α and granzyme B in tumor tissues. N = 4 per group. (c) Tumor cell apoptosis is indicated by terminal deoxynucleotidyl transferase dUTP 
nick end labeling. This is a representative of three independent experiments. (D) Activation of caspase-3 in tumor tissues. Left panel: representative Immunoblot 
image. Right panel: statistics of caspase-3. N = 5 per group. (e,F) Tumor cell proliferation is demonstrated by Ki67 staining. Tumor implants were digested as 
described in Section “Materials and Methods.” Then the whole tissue was pressed through a 70-μm nylon mesh to prepare a single cell suspension, followed by 
staining with APC anti-CD45 and APC anti-CD31 antibodies. Cells were then stained for Ki67 as described in Section “Materials and Methods.” CD45−CD31− tumor 
cells were shown here. Representative histograms are shown in panel (e), and statistical analysis for Ki67+ cells were shown in panel (F). N = 7 per group 
(*p < 0.05; **p < 0.01; ***p < 0.001).
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Far Red and were 1:1 mixed with unlabeled control CD8+ T cells 
(Figure 4A). Then, the T cell mixture was adoptively transferred 
into recipient Rag1−/− mice which had Hepa-1c1c7 tumor 
implants. Three days after transfer, intratumoral T cells were ana-
lyzed. The ratio between CellTrace Far Red-positive and -negative 
intratumoral T cells was close to 1:1 (Figures 4B,C), suggesting 
that Rik overexpression did not change recruitment of CD8+ 
T cells into tumor sites. Interestingly, production of TNF-α and 
granzyme B was decreased in Rik-overexpressing CD8+ T cells, 
while perforin expression was not changed (Figures  4D,E). 
Consistent with the downregulation of cytotoxic mediators, 
when sorted Rik-overexpressing CD8+ T  cells were cocultured 
with Hepa-1c1c7 cells, they induced less Hepa-1c1c7 apoptosis 
than control CD8+ T cells did (Figure 4F). Taken together, Rik 
impaired cytotoxic activity in Hepa-1c1c7 implants.
rik expression in cD8+ T cells is 
Beneficial for Tumor survival
Control CD8+ T cells and Rik-overexpressing CD8+ T cells were 
periodically transferred into recipient Rag1−/− mice that 
were bearing Hepa-1c1c7 tumor implants, respectively. One 
week after the last cell transfer, evaluation of tumor size indi-
cated larger tumors in mice receiving Rik-overexpressing CD8+ 
T cells, compared with tumors in mice receiving control CD8+ 
T  cells (Figure  5A). In mice receiving Rik-overexpressing 
CD8+ T cells, TNF-α and granzyme B levels in tumor implants 
were less than those in mice receiving control CD8+ T  cells 
(Figure 5B). Consistently, TUNEL demonstrated less apoptotic 
tumor cells in mice receiving Rik-overexpressing CD8+ T cells 
(Figure 5C), and less caspase-3 activation was also observed in 
the same group (Figure 5D). With regard to tumor cell prolif-
eration, although there was a trend of increase of Ki67-positive 
tumor cells in mice receiving Rik-overexpressing CD8+ T cells 
relative to mice receiving control CD8+ T cells, the change was 
statistically insignificant (Figures 5E,F).
rik inhibits nuclear Translocation of 
cleaved notch2
The differential in vitro and in vivo effects of Rik on CD8+ T cells 
suggest that Rik might work on certain signal pathways other than 
TCR/CD3/CD28 signaling. Notch signaling has been considered 
crucial for cytotoxic T cell differentiation (23). Moreover, a previ-
ous paper implies that human TC1 blocks the entry of activated 
Notch2 into the nuclei of cancer stem cells (19). To test if this 
mechanism also underlies the in vivo effect of Rik on CD8+ T cell 
function, we firstly analyzed the expression of several North target 
genes such as HES1, HES6, and HEY1 in CD8+ T cells after stimu-
lation with immobilized DLL1, which is a ligand for both Notch1 
and Notch2. In the absence of DLL1, Rik-overexpressing CD8+ 
T cells and control CD8+ T cells expressed comparably low levels 
of HES1, HES6, and HEY1 (Figure 6A). In the presence of DLL1, 
Rik-overexpressing CD8+ T cells expressed lower HES1, HES6, 
and HEY1, in comparison with control CD8+ T cells (Figure 6A). 
However, we found that Rik overexpression did not significantly 
alter the expression of Notch and NICD in the whole cell lysates 
(Figures 6B–D). Rather, analysis of cytosolic and nuclear NICD 
revealed more cytosolic NICD2 and less nuclear NICD2 in Rik-
overexpressing CD8+ T cells, while NICD1 distribution was not 
changed (Figures 6E,F). Immunofluorescent staining showed less 
staining of nuclear NICD2 in Rik-overexpressing CD8+ T cells 
(Figure 6G). Moreover, it seems that Rik might directly bind to 
NICD2 (Figure  6H), suggesting that the mechanism by which 
human TC1 modulates cancer stem cells might also be involved 
in Rik-mediated regulation of CD8+ T  cell function. Notably, 
nuclear NICD2 level was also decreased in Rik-overexpressing 
CD8+ T cells in vivo, in comparison with control CD8+ T cells 
(Figure 6I).
antigen-Presenting cells and TgF-β 
induce rik expression in cD8+ T cells
To roughly determine the possible extracellular factors that con-
tributing to Rik expression, CD8+ T cells were cultured in vitro 
with BALB/c splenocytes depleted of T cells in the presence or 
absence of TGF-β. Splenocytes or TGF-β alone had no effect 
on Rik expression, while splenocytes plus TGF-β moderately 
enhanced Rik expression (Figure 7A). We then tested whether 
treatment with agonistic antibodies and TGF-β had similar effect 
on Rik induction. To our surprise, agonistic antibodies with TGF-
β failed to upregulate Rik expression (Figure 7B), suggesting that 
CD3/CD28 signaling might not be sufficient for Rik expression. 
Taken together, our results implied that TGF-β worked together 
with unidentified antigen-presenting cell-derived factors to 
induce Rik expression in CD8+ T cells.
DiscUssiOn
In this study, we identified the presence of Rik in intratumoral 
CD8+ T cells. Rik is the homolog of human TC1 which regulates 
various tumor cell proliferation and differentiation. Recently, it 
was reported to be involved in hematopoietic stem/progenitor 
FigUre 6 | rik inhibits nuclear translocation of notch2 intracellular domain (nicD2). (a) mRNA levels of HES1, HES6, and HEY1 in CD8+ T cells. 
Lentivirus-transduced CD8+ T cells were stimulated in vitro with immobilized delta-like 1 (DLL1) for 4 h before quantitative polymerase chain reaction. L-S: CD8+ 
T cells transduced with scramble lentiviruses. L-R: CD8+ T cells transduced with Rik-expressing lentiviruses. V: vehicle. D: DLL1. N = 3 per group. (B) Expression of 
Notch1, Notch2, NICD1, and NICD2 in the whole cell lysates after 1-h stimulation with DLL1. This is a representative of two independent experiments. (c,D) Cell 
surface expression of Notch1 and Notch2 after 4-h stimulation with DLL1. Representative histograms are shown in panel (c), and statistics of mean fluorescent 
intensity is shown in panel (D). N = 3 per group. (e,F) Expression of NICD1 and NICD2 in the cytosol and nucleus of CD8+ T cells after 1-h stimulation with DLL1. 
Representative Immunoblot images are shown in panel (e), and statistical analysis is shown in panel (F). N = 4 per group. (g) Fluorescent microscopy of Notch2. 
The polyclonal anti-Notch2 antibody recognized both intact Notch2 and NICD2. N: naïve CD8+ T cells. D: DLL1-stimulated CD8+ T cells. (h) Immunoprecipitation of 
Rik and detection of NICD2. This is a representative of two independent experiments. (i) Nuclear NICD2 levels in isolated intratumoral CD8+ T cells from 3 individual 
mouse of each group. Left panel: representative Immunoblot image. Right panel: statistics of nuclear NICD2 levels. L-S: mice receiving control CD8+ T cells. L-R: 
mice receiving Rik-overexpressing CD8+ T cells (**p < 0.01; ***p < 0.001).
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cell expansion and hematopoiesis (21). Other tumor-or-stem 
cell-related proteins, such as members of Wnt (24, 25), Notch 
(23, 26), and Hedgehog (27, 28) families, as well as Myc (29, 30) 
and KLF4 (31, 32), have been previously shown to be essential 
for mature T cell activation and function. It is likely that T cell 
activation requires several tumor-or-stem cell-related signal 
pathways to modulate expansion and differentiation toward effec-
tor T cells. The upregulation of Rik in intratumoral CD8+ T cells 
therefore might be a consequence of the overall change of cell 
signaling in activated CD8+ T cells. Indeed, we found that Rik was 
FigUre 7 | antigen-presenting cells and TgF-β are necessary for upregulation of rik expression. (a) Rik expression in CD8+ T cells after treatment. Left 
panel: representative Immunoblot image. Right panel: statistics. Fresh: freshly isolated CD8+ T cells. N: no activation. A: activation with BALB/c splenocytes 
depleted of T cells. V: phosphate-buffered saline (PBS). N = 3 per group. (B) Rik expression in CD8+ T cells after treatment with agonistic antibodies or BALB/c 
splenocytes. Left panel: representative Immunoblot image. Right panel: statistics. Abs: agonistic antibodies. Cells: BALB/c splenocytes. V: PBS. N = 3 per group 
(*p < 0.05; ***p < 0.001).
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predominantly expressed in the CD44+CD62L− subpopulation 
of intratumoral CD8+ T cells. This subpopulation represents the 
activated/effector cells which possess potent antitumor activity. 
Interestingly, Rik expression was not upregulated in the splenic 
CD8+CD44+CD62L− T  cells, suggesting that Rik was induced 
by the tumor microenvironment, or Rik was expressed only in 
tumor-specific CD8+ T cells.
To our surprise, Rik overexpression did not impact agnostic 
antibody-induced CD8+ T  cell activation. This result strongly 
suggests no involvement of Rik in CD3/CD28-mediated cell 
signaling. Another possibility is that CD3/CD28-mediated cell 
signaling was too strong to be overcome by the effect of Rik in the 
in vitro study, since the agonistic antibodies induced very robust 
activation. Our ongoing research is testing whether suboptimal 
activation could be influenced by Rik overexpression. However, 
in vivo experiments indicated the negative role of Rik on CD8+ 
T cell function. The differential results of in vitro and in vivo study 
imply that the effect of Rik depends on several tissue-or-tumor-
associated factors. It would be possible that in vitro settings lacked 
these necessary factors so the effect of Rik could not be seen. 
Indeed, in the following study, we identified the role of Notch 
signaling in Rik-mediated T cell regulation. So, it is likely that 
in  vitro stimulated CD8+ T  cells do not have sufficient Notch 
signaling for Rik to inhibit.
Interestingly, a recent study demonstrates the suppressive 
effect of human TC1 on Notch2 signaling in liver cancer stem 
cells (19). Moreover, the role of Notch2 in regulating CD8+ T cell 
function has been extensively studied. It is reported that antigen-
presenting cells, especially dendritic cells, express Notch ligands 
Jagged1 and Delta-like 4, whereas naive CD8+ T  cells express 
Notch2 (23). Inhibition of Notch during activation reduced fre-
quencies of IFN-γ-, TNF-α-, and granzyme B-producing CD8+ 
T cells (23). More importantly, it has been shown that signaling by 
Notch2 but not Notch1 in CD8+ T cells is required for antitumor 
cytotoxic T lymphocyte responses, because specific knockout of 
Notch2 in CD8+ T cells decreases antitumor cytotoxic T lympho-
cyte responses while specific knockout of Notch1 does not (33). 
Notably, in HCC sites, the sources of Notch ligands might include 
antigen-presenting cells (20), HCC cells (34), or vascular endothe-
lial cells (35, 36). Intratumural CD8+ T cells might engage Notch 
ligands through their surface Notch1 and Notch2. These reports 
led us to explore the potential mechanism of Rik’s effect. Similar 
to what was observed in liver cancer stem cells, reduced nuclear 
translocation of NICD2 was found in Rik-overexpressing CD8+ 
T cells upon in vitro stimulation with Notch2 ligand DLL1. And 
decreased nuclear NICD2 was also seen in Rik-overexpressing 
CD8+ T cells in vivo. Taken together, Rik might modulate CD8+ 
T cell function through the same mechanism as it works on liver 
cancer stem cells.
Notably, we found that Rik expression could be induced by con-
current presence of T cell-free splenocytes and TGF-β. Although 
this experiment was actually a one-way mixed lymphocyte 
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reaction rather than a tumor antigen-specific immune response, 
we think it still provides important information on the expression 
of Rik in CD8+ T cells. It should be noted that agonistic antibod-
ies with TGF-β was unable to induce Rik expression, suggesting 
that splenocytes might provide extra signals in addition to TCR/
CD28 signaling to trigger Rik expression. The exact identity of 
these signals, and whether they are cell surface proteins or soluble 
mediators, is still unknown. To more accurately characterize the 
role of antigen-presenting cells in the induction of Rik, geneti-
cally engineered mouse strains such as OT-I mouse, and special 
tumor cell lines such as OVA (257-264)-expressing mouse HCC 
cell lines, will be very helpful. However, we are currently unable 
to acquire these materials. Our lab is establishing several mouse 
HCC cell lines expression OVA, and we hope to buy the OT-I 
mouse strain in future.
With regard to TGF-β, a previous research also showed that 
TGF-β upregulates human TC1 expression in colon cancer (14). 
TGF-β has long been considered a crucial contributing factor to 
carcinogenesis of HCC (37) and a suppressive agent for CD8+ 
T cells (38). Besides, upregulated TGF-β expression is observed in 
HCC (39–41). Most hepatocarcinoma cells are able to synthesize 
and secrete TGF-β continually by themselves. Therefore, it is very 
likely that in the HCC sites, HCC-derived TGF-β collaborates 
with antigen-presenting cells to enhance Rik expression in tumor-
specific CD8+ T cells. To test this hypothesis, our lab is trying to 
isolate antigen-presenting cells, particularly dendritic cells from 
tumor implants so as to coculture them with intratumoral CD8+ 
T cells in the presence of TGF-β. However, it is very difficult to do 
so due to the limited abundance of intratumoral dendritic cells. 
Chemical-induced HCC model might be an alternative. Another 
possibility is that tumor cells, which present their MHC-I–anti-
gen complex and express TGF-β, could effectively induce Rik 
expression in tumor-specific CD8+ T cells. Our lab will also test 
this hypothesis in future.
Besides Notch2 signaling, human TC1 has been indicated to 
regulate Wnt/β-catenin (15, 42) and NF-κB pathways (43). These 
pathways are also important for CD8+ T cell activity. The potential 
role of Rik in modulating these pathways in CD8+ T cells should 
be elucidated in further research. In conclusion, our study unveils 
a novel mechanism by which anti-HCC activity of CD8+ T cells 
is impaired. Our data might shed light on development of new 
therapeutic approaches to promote anti-HCC immunity.
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